Always up to date.

Our goal is to develop procedure and anatomy specific devices that lead in collaboration with our customers to predictable and superior treatment outcomes. Read on to learn more about our solutions, priorities, partnerships and how we create sustainable value with our teams.

Medartis reports 20% sales growth and makes further progress in strengthening its US organisation

  • Total net sales in the first half of 2022 increased by 20.1% or 18.0% excl. NSI (both in CER[1])
  • Strong growth in EMEA led to further market share gains and dynamic LATAM accelerated APAC...
Read more

Medartis completes acquisition of Nextremity Solutions Inc. and announces new US leadership

Basel, Switzerland, 3 May 2022 - Medartis Holding AG (SIX: MED) announced today that it has completed the acquisition of Nextremity Solutions Inc., a strategic commercialisation organisation located...

Read more

Medartis has decided not to pursue the convertible bond placement

Ad hoc announcement pursuant to Art. 53 LR

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The...

Read more